Drugs / Copper Cu 64 TP3805
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT03039413 | Sep 2016 → May 2019 | urinary bladder cancer, urothelial carcinoma | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT02810873 | Sep 2008 → May 2012 | breast carcinoma | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Copper Cu 64 TP3805 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03039413 ↗ |
| Modality | Diagnostic / imaging agent | “Diagnostic procedures, such as positron emission tomography (PET) and positron emission mammography (PEM) scan, using Cu-64-TP3805 may help doctors find and diagnose breast cancer.” NCT02810873 ↗ |
| Route | Intravenous | “Given IV” NCT03039413 ↗ |